In contrast, there is considerable excitement around the ability of RPT to overcome radioresistance through delivering alpha particle therapy (e.g., Ra‐223 for bone metastasis and Ac‐225‐PSMA for prostate cancer). Here, FOLH1 is linked to prostate carcinoma.